Original Publication Date: 1 March, 2014
Publication / Source: CNS Oncology
Authors: Rheal A Towne &, Jonathan D Wren
A total of 40% of all primary CNS tumors are diagnosed as gliomas, with glioblastomas (GBM) being the most malignant . There is a very poor survival time of approximately 15 months for most patients diagnosed with GBM . The malignant nature of high grade gliomas makes them one of the leading causes of cancer death . To classify tumors and assess prognosis, differences in molecular composition, or ‘biomarkers’, between tissue types can be used diagnostically to assess and manage adult malignant gliomas [2–7].